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INTRODUCTION
Apoptosis is a highly regulated process important in embryonic and immune system development and tissue homeostasis. [1] [2] [3] [4] This process is characterized by specific morphologic changes such as cell size compaction, chromatin condensation, DNA degradation, membrane blebbing and cell fragmentation into apoptotic bodies. The principal biochemical effectors of apoptosis are the caspases, that are synthetized as inactive zymogens that once activated cause the degradation of a variety of intracellular substrates and produce cell death. [5] [6] [7] [8] [9] [10] It is accepted that tumor growth may principally be due to reduced rates of cell death rather than to enhanced proliferation. [11] [12] [13] The process of apoptosis is now recognized as an important component of multi step carcinogenesis. 3, [14] [15] [16] [17] [18] However, most cancer chemotherapy regimens make use of highly cytotoxic drugs that target proliferating cell populations. The non-discriminatory nature of these agents leads to severe side effects in normal cells with a high proliferative index, such as those of the gastrointestinal tract and bone marrow, thus limiting the effective dose of anticancer drug that can be administered. 19 In the search of less toxic anticancer therapies, we have looked for novel compounds with anticancer activity based on a proapoptotic mechanism. In the design of these new structures, a general pattern has been adopted. These molecules have a central nucleus made up of an aromatic system, the ring of quinazoline, connected to two identical lateral arms consisting of an amine aliphatic chain of variable length and flexibility with or without heterocycles at the end of the chain. Recently, we have described the synthesis of symmetrical derivatives as cytotoxic and apoptosis inducers. 20, 21 In our search for new molecules with these activities, we have synthesized new derivatives of quinazoline 2,4-difunctionalized (unpublished results).
The central nucleus of quinazoline is involved in numerous biological activities, mainly in cancer, as the inhibition of folate metabolism and the inhibition of the tyrosine kinase activity, apoptosis induction and topoisomerase inhibition. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] The cytotoxicity of thirteen derivatives of quinazoline was evaluated. After confirmation of their implication in apoptosis and their lack of toxicity against non-tumoral human cell lines, 2,4-dibenzylaminoquinazoline (referred as JRF12) was chosen for the further study New Symmetrical Quinazoline Derivatives Selectively Induce Apoptosis in Cancer Cells of its mechanism of action because of its suitable apoptotic and cytotoxic profile.
MATERIAL AND METHODS
Cell lines and reagents. The five human cell lines were obtained from the American Tissue Culture Collection (Manassas, VA): HT29 (ATCC HTB 38) is a colon adenocarcinoma cell line, T24 (ATCC HTB-24) was obtained from urinary bladder cancer, MDA-MB-231 (ATCC HTB26) was established from adenocarcinoma of mammary gland , CRL8799 was obtained from breast epithelium (ATCC 184B5) and CRL11233 (ATCC THLE-3) from human liver.
HT29 and T24 cells were cultured in McCoys medium (Gibco), MDA-MB-231 in Leibovitz (Gibco), CRL8799 in MEG (Clonetics Corporation) and CRL11233 in BEGM (BEGM Bullet kit, Clonetics Corporation). These media were supplemented with 10% fetal bovine serum, penicillin (50 U/ml) and streptomycin (50 µg/mL). Cells were grown as monolayer in 175 cc flasks (Corning) and were incubated at 37˚C in a humidified atmosphere containing 5% CO 2 .
The evaluated compounds were dissolved in dimethyl sulfoxide (DMSO). The DMSO concentration was equalized in all media. In all cases, the concentration of solvent in culture medium did not exceed 0.5% (v/v).
Cytotoxicity study. Cytotoxicity was determined by using the neutral red assay as described by Lowik et Albas. 37 Ninety-six well flat bottom tissue culture plates (Microtest 96 Falcon, Becton Dickinson) were used for the experiments. Cells were resuspended in culture medium and 180 µL of cell suspension were added into each well. Cells were seeded at a density of 20 x 10 3 /well, and then cultured for 14 h to assure similar attachment of all cells. Test agents or vehicle were then added to the cells in 20 µL of culture medium and incubated for 72 h. After washing with PBS, the cells were incubated at 37˚C with neutral red during 1. 5 h. The dye was then extracted from the cells by the addition of 100 µL 0.05 M NaH 2 PO 4 in 50% ethanol. Optical density was measured at 540 nm and 650 nm was used as a reference wavelength using a microtiter plate reader (Organon tecknica). The spectrophotometer was blanked on the first column of control wells containing solvent solution alone. 38, 39 Survival percentage was determined at the screening concentrations of 20 and 100 µM, using the survival percentage obtained with the cells treated only with the solvent (DMSO at 0.5%) as reference. The results are expressed as the average of triplicate assays. IC 50 values were calculated for those compounds showing less than 50% survival in the cell lines at 100 µM concentration. This value was determined in triplicate by curvilinear regression analysis using the statistical program SPSS 11.0.
With regard to selectivity, cytotoxicity was determined in cell cultures of two non-tumoral lines, CRL-7899 and CRL-11233. The highest IC 50 calculated in the three tumoral lines was selected as the test concentration for assays on non-tumoral cells. The IC 50 obtained in MDA-MB-231 was evaluated in breast non-tumoral cells.
Colony formation assay. The different cell lines were seeded in six-well plates (Falcon, Becton Dickinson), cultured for 14 h and treated for 24 h with vehicle or with the IC 50 of JRF12. Cells were then washed, fresh medium was added and incubation was continued for 7 days.
Cells were fixed with 100% methanol for 2 minutes and then stained with 1% toluidine blue. Colonies were counted and expressed as the percent survival relative to non-treated cells. Cell viability is expressed as medium ± SD of percent colonies formed 7 days after treatment, referred to control cells. Each experiment was performed by triplicate.
DNA fragmentation analysis. DNA fragmentation was measured at 48 h after treatment using the Cell Death detection ELISA PLUS kit (Roche Diagnostics, Indianapolis, IN) exactly as recommended by manufacturer. [40] [41] [42] In brief, the different cell lines were seeded in 96-well plates (2 x 10 4 cell/well). The cells were treated with various drugs at the IC 50 for 48 h and then, after lysis in 200 µL lysis buffer for 30 min at room temperature; the lisates were centrifuged at 200 g for 10 min and after that, 20 µL from the supernatant were transferred to streptavidin-coated microtitre plates for analysis. Eighty microliters of the inmunoreagent containing monoclonal antibodies directed against DNA and histones were added to each well, and the plates were incubated on a shaker (300 r.p.m.) for 2 h at room temperature. The solution was then removed and the wells were rinsed three times with incubation buffer. One-hundred microliters of substrate solution were added to each well and after 10-20 min, the amount of citosolic mono-and oligonucleosomes (indicator of cell death) was determined spectrophotometrically at 405 nm using substrate solution as blank.
Measurement of caspase-3 activity. Detection was carried out by means of cytometry, using the Active-Caspase-3 FITC Mab apoptosis kit (Pharmingen), according to manufacturer, which evaluates the number of cells that contain the dimerized and activated form of caspase-3. The range of effective measurements for this enzyme was found to be between 14 and 48 h. Therefore, measurements were taken at 14, 24 and 48 h, and the obtained values were compared with those of control cells incubated without the test compounds. The test concentrations correspond to the IC 50 values determined in the cytotoxicity assay. Cytometry was performed on a FACSCAN (Becton Dickinson).
Measurements of central caspases activity. Caspase-3 assays were carried out in plates of 9 cm diameter (Cellstar Greiner Bio-one). Cells were harvested by using a 0,25% trypsin/0,03 EDTA solution and then lysed with a buffer containing 1%Triton (100x); 50 mM Tris HCl pH8, 150 mM NaCl, 100 µg/mL PMSF and 1mM DTT. The soluble fraction of the cell lysate was then assayed for caspase-3 activity using Ac-DEVD-pNA, a colorimetric substrate for caspase-3. Eighty micrograms of protein were diluted in 50 µL of caspase-3 buffer containing 50 mM HEPES pH 7,4; 100 mM NaCl, 0,1% CHAPS, 10 mM DTT, 1 mM EDTA, 10% glycerol. Fifty microliters of the substrate, DEVD-pNA (Biomol) was added to a final concentration of 200 µM, and the plates were incubated for 24 h at 37˚C and 5% CO 2 . Levels of released p-nitroanitrile (pNA) were measured as absorbance at 405 nm. To confirm the correlation between caspase-3 activity and signal detection, control reactions were performed by addition of 1 µL of 1 mM DEVD-CHO (Biomol), an inhibitor of caspase-3, to the diluted protein samples followed by addition of the reaction buffer and incubation at 37˚C for 30 min before adding the caspase-3 substrate. 6, 43, 44 Morphological characteristics: Caspase-3 and nuclear staining. In order to evaluate nuclear morphology, cells were treated with the IC 50 of the compound during the time of caspase-3 activation. Cells were washed with PBS, fixed with cold methanol at room temperature for 15 minutes, then washed with PBS and post-fixed and permeabilized with methanol/acetone during 10 minutes. After blocking with 1% BSA and 0,1% Tween 20 in PBS, 10 µg/mL of primary antibody against caspase-3 (Sta Cruz Biotechnology) (10 µg/mL) were applied using anti-IgG antibody as negative control at a dilution of 1:1000.
After overnight incubation at 4˚C overnight the antibody was rinsed and washed with PBS (1% BSA), then treated 60 minutes with antirabbit antibody at 1:1000 dilution (Jackson, Inmunoresearch laboratories, INC). Further, it was washed with PBS and stained with 4'6-diamidino-2-phenylindoline (DAPI) 1:10 dilution in PBS and glycerol. The nuclear morphology was visualized using fluorescence microscopy.
Specific inhibition of caspases. To determine the involvement of caspase-8 and caspase-9 in proapoptotic activity, a specific inhibitor of each caspase, Z-IETD-FMK and Z-LEHD-FMK respectively and a general caspase inhibitor (Z-VAD-fmk) were added 4 hours before treating with JRF12; all of them were purchased from Calbiochem (SanDiego, CA, USA). Vehicle DMSO at a final concentration of 0.5% was included as control. The effect of these inhibitors was estimated by measuring cytotoxicity with neutral red assay as described above. The experiment was performed treating cells with the caspase inhibitors (100 µM) and 1.5 x IC 50 JRF12 during 48 h, or with 25 µM of caspase inhibitors and 2 x JRF12 IC 50 during 24 h.
Cell cycle analysis. Single cell suspensions were obtained from cell monolayers as follows. First, cells were washed with PBS and then incubated 5 minutes with trypsin. Cells were collected from the dishes in the presence of PBS and were washed and resuspended in 1 mL of PBS. For cell cycle analysis, cells were fixed with ice-cold 100% ethanol and incubated at 4˚C for 15 minutes. Cells were then resuspended in 125 µL of ribonuclease type IIA and incubated at 37˚C for 15 minutes, then resuspended in 125 µL of propidium iodine (25 µg/mL) and incubated at room temperature for 30 minutes in obscurity. Before DNA content analysis cells were filtered by 40 µm nylon mesh filter. The analysis was performed on a Becton Dickinson FACScan flow cytometer using the CellQuest Software. All the results were obtained from three independent experiments.
Oligonucleotide microarrays. The different cell lines were seeded at a rate of 8 x 10 6 per flask, grown during 14 h and then were treated with DMSO (vehicle control) or IC 50 of JRF12 for two different times (caspase-3 activation and DNA fragmentation). The rationale for choosing these time points was to capture gene expression profile of early response genes, and those involved in the induction of apoptosis.
Total RNA from each sample was isolated using the RNeasy Midi Kit and RNAse-free DNAse Set (QIAGEN, Valencia, CA) according to the manufacturer's protocols. The RNA concentration was calculated by spectrophotometry and it was adjusted to 1 µg/µL. Quality control of RNA integrity was performed by electrophoresis on a 2% agarose gel using ethidium bromide staining.
The 3DNA Submicro Oligo Expression Detection Kit (Genisphere) was used to perform the reverse transcription as recommended by manufacturer; afterwards, cDNA was prehybridized with the fluorescent reactive 3DNA. Then, the samples were hybridised to the slides from the centre for Applied Genomics of the University of New Jersey. These slides contain 18.861 oligos. After overnight hybridization at 50˚C in a slide cassette (Telechem, Sunnyvale, CA), slides were washed sequentially in a series of solutions with increasing stringency: 2x SSC, 0,2% SDS during 5 min at room temperature; 2x SSC 0,2% SDS, 15 min, 42˚C; 2X SSC, during 10 min at room temperature; and finally 0,2 × SSC during 10 min at room temperature.
To remove the systematic bias caused by the chemical difference between Cy3 and Cy5, each microarray study was performed twice using dye-swap.
Microarray data acquisition, normalization and analysis. The hybridized slides were scanned with the GMS 418 scanner (Genetic Microsystems, Woburn, MA). After image acquisition, the scanned images were imported into "ImaGene 4.1" software (BioDiscovery) to quantify the signal intensities. Data from spots not recognized by the Imagene analysis software (empty, poor and negative spots) were excluded from further considerations. We also removed data from spots identified as visually flawed. The fluorescent median signal intensity for each spot was calculated using local median background subtraction. Data were normalized using Global mean, Dye-swap Pairs normalization and Dye Swap Fix filter 1.5 with the program ArrayNorm 1.7 (Graz, Austria). 45 Log ratios above 1.7 or below -1.7 were considered as differential expression.
The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (GEO, www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series accession number GSE3329. Quantitative RT-PCR. The same RNA prepared for microarray analysis was also used for real-time RT-PCR. 2 µg of total RNA were used to generate cDNA using the Taqman Reverse transcription Reagent Kit (PE Applied Biosystem, Foster city, CA) according to the manufacturer's protocol. Each cDNA sample was analysed in triplicate using the Abiprism7700 sequence detector (PE Applied Biosystems). Quantitative assessment of DNA amplification was performed using Taqman Master Mix (PE Applied biosystems). The Q-RT-PCR reactions were carried out in a total volume of 25 
Fold induction was calculated using the formula 2 -∆∆Ct , were ∆Ct = target gene Ct -"housekeeping gene" Ct, and ∆∆Ct is based on the mean of respective controls. The Ct value is determined as the cycle at which the fluorescent signal emitted is significantly above background levels and it is inversely proportional to the initial template copy number.
Statistics. Data are presented as mean ± SD. IC 50 values were analysed using a non-linear regression model. Non-parametric or parametric test were performed according to the normality test results. The SPSS 11.0 software was used for all statistical analyses.
RESULTS

Cytotoxicity.
The cytotoxic activity of the synthesized quinazoline derivatives was determined in the three human cancer cell lines at 100 and 20 µM using the neutral red assay. All compounds were toxic in the three cell lines tested. The IC 50 values of the compounds are shown in Table 1 . We used camptothecin as reference substrate, its IC 50 values were 0.291 µM in MD-MB-231; 0,014 µM in HT-29 and 0.006 µM in T-24.
All the compounds showed good activity against all cancer cell lines tested, with IC 50 values no higher than 30 µM.
Apoptosis detection: Caspase-3 activity and DNA fragmentation. Once the cytotoxicity of the compounds was verified, the induction of apoptosis was studied. Caspase-3 is believed to serve as a general mediator and is activated early during apoptosis. It is often considered the key executioner apoptosis because of its ability to cleave a vast array of proteins. 5, 46 The levels of this enzyme were measured at 14, 24 and 48 h. Five compounds activate caspase-3 in T24: JRF7, JRF8, JRF9, JRF10 and JRF12, and three in the HT29 cell line: JRF9, JRF10 and JRF11. For MDA-MB-231 cells the cytometry could not be performed due to the obstruction of the cytometer by the conglomerates these cells form in suspension.
The ability to induce DNA fragmentation in cell culture was tested using the Cell Death detection Elisa Plus Kit (Roche). The level of DNA degradation measured in the control culture was considered as 1. showed this effect in MDA-MB-231. Only JRF5 was able to induce DNA degradation in the three cancer cell lines while JRF12 and JRF15 showed this effect in two cell lines.
Selectivity. In order to study the degree of selectivity, the cytotoxicity of the compounds was tested in cell cultures of two non-tumoral lines: CRL-8799 and CRL-11233, selected because they constitute an in vitro model often used for pharmacotoxicological studies. 47 Survival values were between 90% and 100% for JRF3, JRF4, JRF6, JRF8 and JRF12 in CRL8799 at IC 50 ( Table 2) .
The best values were obtained with the compounds JRF8, JRF12 and JRF15. At the highest concentration, JRF8 was not toxic in CRL-8799 but toxic in CRL11233; inversely JRF15 was not toxic in CRL11233, being toxic in CRL8799. The compound JRF12 was not toxic in either cell line.
JRF12, 2,4-dibenzylaminoquinazoline ( Fig. 1 ), was selected due to its ability to induce at least one apoptotic event in the three tumor cell lines tested, being not citotoxic for the non-neoplasic cell lines.
Colony formation assay. We evaluated the effects of JRF12 on cell growth by colony formation assay. The colony number decreased to 18 ± 0.04% and 11 ± 0.04% in T24 and HT29 cells respectively, and a viability of 72 ± 0.02% was observed in MDA-MB-231.
There is a remarkable inhibition of cell growth both in T24 and in HT29, but these effects are less severe in MDA-MB-231, in which the viability decreases only a 28%. Time course analysis of JRF12 apoptosis induction: DNA fragmentation and caspase-3 activation. In T24 cells treated with the IC 50 dose of JRF12, DNA degradation began at 14 h and reached its maximum value at 28 h. This effect did not disappear until 38 h. The effect is slower in HT29, where it began at 24 hours reaching its highest value at 28 hours and did not finish until 44 hours. In the breast cell line, MDA-MB-231, we have only found significant differences at 16 hours. This result agrees with those found for all the compounds evaluated previously that showed a minimal effect in this cell line.
We used a colorimetric enzymatic assay to measure changes of caspase-3 activity between extracts prepared from control and JRF12 treated cells. Cells were treated with their corresponding IC 50 at different times. JRF12 stimulates caspase-3 like activity in the three cell lines. In a time course study, at the IC 50 dose of JRF12 caspase-3 activity reached a peak after 18 h of treatment in T24, while in HT29 this peak appeared at 24 h and after 10 hours in MDA-MB-231, which correlated with the inmunofluorescence results.
The above results indicate that caspase-3-like proteases were activated in response to treatment with JRF12. To confirm that the obtained signal was due to caspase-3-like protease activity, caspase-3 inhibition by DEVD-CHO was evaluated showing a complete decrease of activation. 6, 44, 48 Inmunofluorecence studies. We also examined the activation of caspase-3 by inmunofluorescence and the nuclear morphology of dying cells with the fluorescent DNA-binding agent, DAPI. As shown in Figure 2 , after IC 50 treatment during the time of caspase-3 activation in each cell line, T24 cells clearly exhibited nuclear segmentation and chromatin condensation, classical features of apoptosis, and activation of caspase-3. No altered nuclear morphology was observed in control cells treated with the vehicle. Thus, this result confirms that JRF12 cytotoxicity is mediated through the initiation of the apoptotic program, corroborating the results obtained previously.
Effect of caspase inhibitors on JRF12-induced apoptosis. To determine the involvement of caspases 8 and 9 in the cell death induced by JRF12, and therefore the pathway the compound is activating, we examined the effects of specific inhibitors, Z-IETD-FMK for caspase-8 and Z-LEHD-FMK for caspase-9. We moreover examined the effects of the general inhibitor of caspases Z-VAD-FMK on cell viability (Fig. 3) . It was evaluated at 24 and 48h.
As measured by cell viability, all the caspase inhibitors assayed prevented induction of apoptosis after treatment with JRF12. The general caspase inhibitor, Z-VAD-FMK, inhibits cell death in the three cell lines evaluated, confirming that caspases are implicated in cell death induced by JRF12. Caspase-8 and caspase-9 inhibitors also inhibit cell death. The effect of caspase-8 is greater than that of caspase-9 in the three cell lines tested, suggesting that JRF12 activates cell death by caspase-8.
Cell cycle progression. Flow cytometry analysis showed that the treatment with IC 50 JRF12 for 30 h induces a progressive timedependent accumulation of cells in G 2 /M in HT29 cell line (Table 3) . G 2 cell population increased from 37% in the control to 55% in the presence of the IC 50 dose of JRF12. In the mean time, cells in G 1 and S phase gradually decreased; G 1 percentage was 51% at time 0 and decreased to 33% at 24 hours. Cells were treated with IC 50 dose of 2,4-dibencilaminoquinazoline for different times and analyzed by flow cytometry and the percentages of distribution of cell cycle were reported. Data are representative of three independent experiments.
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In T24 cells (Table 3) , there was a decrease in the number of cells in G 1 , but not an increase in the number of cells in G 2 . Nevertheless, a characteristic hypo-diploid DNA content peak (sub-G 1 ) can be easily detected at 24 h, time at which we have detected activation of apoptosis previously. The slight decrease in the G 2 /M cell population observed at 24 and 30 h could be explained by a decrease in the cell G 2 phase entering due to apoptosis.
Microarrays analysis. To determine whether gene expression was affected by JRF12 treatment in the three cell lines, we used oligonucleotide arrays. The different cell lines were treated with the IC 50 value of JRF12 for two different times, the first corresponding to caspase activation and the second to DNA fragmentation.
T24 cells were treated during 20 and 24 hours. At 20 h, 2 genes were upregulated in treated cells, while 1 gene was downregulated. At 24 h 2 genes were upregulated and 3 downregulated at the second time (Table 4) .
HT29 cells were treated for 24 and 28 hours. At 24 h, a total of 14 genes were upregulated in treated cells and 15 genes were downregulated. At 28 h, 10 genes were upregulated and 18 downregulated (Table 4) .
MDA-MB-231 cells were treated for 9 and 24 h. 8 genes were upregulated while 11 were downregulated at the first of the time points, and 7 genes were upregulated and 11 genes were downregulated at the second time point (Table 4 ).
The limited number of genes with altered expression suggests that JRF12 may mediate its effects via posttranscriptional mechanisms.
Microarray validation. Quantitative RT-PCR analysis was used to confirm the results of the microarray experiments. The expression of different genes such as ABCB8 in T24, PDCD2 and ITGAL in MDA-MB-231 and RFP2 and ITGB4P in HT29 was evaluated (Fig. 4) . The obtained results were consistent with the microarray data.
DISCUSSION
In this study, our aim was to find a new chemical compound able to induce selective apoptosis in human cancer cells. We synthesized novel symmetrical compounds based on a general pattern derived from a nucleus of quinazoline. These compounds were tested for cytotoxicity against three human cancer cell lines: breast (MDA-MB-231), colon (HT-29), and bladder (T24). All the compounds showed anticancer activity against all of the cell lines tested, with IC 50 values in the low micromolar range. Some compounds exhibited great ability inducing apoptosis, being able to promote caspase-3 activation and DNA degradation. Among them, 2,4-dibenzylaminoquinazoline was the compound showing better selectivity for cancer cells, without toxicity against the non-tumoral cell lines CRL-7899 and CRL-11233. The data reported here also demonstrate that 2,4-dibenzylaminoquinazoline is able to induce an apoptotic response with caspase-3 activation and DNA degradation in at least two cell lines. Both events occurred faster and earlier in T24 cells than in HT29 cells. There is a lower induction of apoptosis in MDA-MB-231 although cell toxicity is present. There are several possible explanations for the discrepancies between the sensitivity of the MDA-MB-231 to JRF12 when measured cell cytotoxicity and realized apoptosis assays: the obtained results suggest that while they appear to be less sensitive to the apoptosis-inducing effects of 2,4-dibenzylaminoquinazoline, MDA-MB-231 cells are somewhat more sensitive to this compound in terms of the absolute decrease in cell number observed in the cytotoxic assays. This implies that additional mechanisms, other than apoptosis, may work in concert with the apoptotic program to cause cell death in this cell line. The differences in the type of cell death induced by 2,4-dibenzylaminoquinazoline may be linked to the diverse types of genetic alterations that occur in the different tumor cell lines.
By determination of cell cycle progression in response to 2,4-dibenzylaminoquinazoline, an increase of G 2 /M arrest was detected in HT29, while in T24 we observed cell death instead of cell cycle arrest. Our study shows that HT29 cells exposed to the IC 50 dose of 2,4-dibencilaminoquinazoline undergo prolonged but transient G 2 /M arrest followed by G 2 to M progression and after that cell death or G 1 progression. Whereas T24 cells exposed to IC 50 dose of 2,4-dibencilaminoquinazoline undergo decreased G 1 population followed by S to G 2 transit and apoptotic cell death.
Our data indicate that 2,4-dibenzylaminoquinazoline induced cell cycle arrest in G 2 and apoptosis may result from the activation of the same signal transduction pathways, because G 2 arrest seems to be followed in both cell lines by apoptosis activation, although this effect is slower in HT29.
To further define the mechanism by which JRF12 promotes the apoptotic pathway, the effect of caspase inhibition was evaluated. In all the cell lines tested the caspase inhibitors partially inhibit cell death. Caspase-8 inhibition was greater than caspase-9 indicating that JRF12 cell death is mainly activated by caspase-8. In the apoptotic cascade, caspase-8 is the most upstream enzyme mediating death receptor apoptosis pathways, and its activation propagates the apoptotic signal by activating executioner caspases such as caspase-3. Caspase-8, in addition to activation of caspase-3, has the ability to cleave BH3 interacting domain death agonist (Bid). The truncated Bid interacts with the proapoptotic protein Bax, inducing a conformational change of Bax that promotes the release of cytochrome c from mitochondria to cytosol, therefore activating caspase-9, which activates executioner caspases. 49 Our preliminary studies using microarray analysis to assess the effects of 2,4-dibencilaminoquinazoline on gene expression found no genes whose expression was altered in the three cell lines at both of the times examined.
Because of the few genes with differential expression we consider that 2,4-dibenzylaminoquinazoline mediate its effect via posttranscriptional changes.
In summary, our results show that 2,4-dibenzylaminoquinazoline stimulates activation of caspase-3 activity and DNA degradation in cancer cell lines, resulting in significant cell death upon continuous treatment with the drug.
Regarding the molecular mechanism of action of 2,4-dibenzylaminoquinazoline, it has been shown that quinazoline derivatives have the ability to inhibit tyrosine kinase activity, being able to interfere with different intracellular signal transduction pathways. 50 For instance, several quinazoline derivatives inhibit the ErbB family of tyrosine kinase proteins. When these receptors are activated, dimerization is followed by activation of intrinsic protein tyrosine kinase activity, tyrosine phosphorylation, and activation of intracellular signal transduction pathways, such as the phosphathidylinositol 3-kinase (PI3K)/ AKT and the ras/raf/ MEK/MAPK pathways. 51 Several quinazoline derivatives may also activate the intracellular effect of the integrin pathway, activating kinases such as FAK and PKB/Akt, that are critical elements of anchorage-mediated survival signaling. 52 These signal transduction pathways finally act phosphorilating, and thereby activating, different proteins related to apoptosis like, for example, MAP phosphorilation of BAD. 33 Recently, it has been shown that these quinazolines derivatives, such as doxazosin, also activate 53 For all this reasons we suggest that 2,4-dibencilaminoquinazoline may act inhibiting some tyrosine kinase like other quinazoline derivatives, altering intracellular signal transduction pathways and indirectly activating apoptosis.
Finally, these results suggest that 2,4-dibencilaminoquinazoline may be attractive as a novel investigational drug, although further studies are required to detail the mechanism of action, animal models of different neoplasms may be useful to characterize the preclinical profile of this apoptosis inducer drug. 
